JP6797122B2 - 安定性が増加されたグルカゴン誘導体 - Google Patents

安定性が増加されたグルカゴン誘導体 Download PDF

Info

Publication number
JP6797122B2
JP6797122B2 JP2017535417A JP2017535417A JP6797122B2 JP 6797122 B2 JP6797122 B2 JP 6797122B2 JP 2017535417 A JP2017535417 A JP 2017535417A JP 2017535417 A JP2017535417 A JP 2017535417A JP 6797122 B2 JP6797122 B2 JP 6797122B2
Authority
JP
Japan
Prior art keywords
glucagon
present
obesity
glucagon derivative
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017535417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504901A (ja
JP2018504901A5 (enExample
Inventor
ジョンクク キム
ジョンクク キム
ジョンミン イ
ジョンミン イ
サンユン キム
サンユン キム
ソンミン ペ
ソンミン ペ
サンヨプ ジョン
サンヨプ ジョン
セチャン クォン
セチャン クォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of JP2018504901A publication Critical patent/JP2018504901A/ja
Publication of JP2018504901A5 publication Critical patent/JP2018504901A5/ja
Application granted granted Critical
Publication of JP6797122B2 publication Critical patent/JP6797122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017535417A 2014-12-30 2015-12-30 安定性が増加されたグルカゴン誘導体 Active JP6797122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140193800 2014-12-30
KR10-2014-0193800 2014-12-30
PCT/KR2015/014422 WO2016108586A1 (ko) 2014-12-30 2015-12-30 안정성이 증가된 글루카곤 유도체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144259A Division JP7079301B2 (ja) 2014-12-30 2020-08-28 安定性が増加されたグルカゴン誘導体

Publications (3)

Publication Number Publication Date
JP2018504901A JP2018504901A (ja) 2018-02-22
JP2018504901A5 JP2018504901A5 (enExample) 2019-02-07
JP6797122B2 true JP6797122B2 (ja) 2020-12-09

Family

ID=56284642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535417A Active JP6797122B2 (ja) 2014-12-30 2015-12-30 安定性が増加されたグルカゴン誘導体
JP2020144259A Active JP7079301B2 (ja) 2014-12-30 2020-08-28 安定性が増加されたグルカゴン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020144259A Active JP7079301B2 (ja) 2014-12-30 2020-08-28 安定性が増加されたグルカゴン誘導体

Country Status (28)

Country Link
US (1) US11135271B2 (enExample)
EP (2) EP3575314B1 (enExample)
JP (2) JP6797122B2 (enExample)
KR (1) KR102291020B1 (enExample)
CN (1) CN107636009B (enExample)
AR (1) AR103322A1 (enExample)
AU (1) AU2015372818A1 (enExample)
CL (1) CL2017001718A1 (enExample)
CO (1) CO2017006308A2 (enExample)
CR (1) CR20170293A (enExample)
DO (1) DOP2017000156A (enExample)
EA (1) EA035527B1 (enExample)
EC (1) ECSP17040923A (enExample)
ES (1) ES2976562T3 (enExample)
GT (1) GT201700150A (enExample)
HK (1) HK1248713A1 (enExample)
IL (2) IL253206B (enExample)
MA (1) MA40709B1 (enExample)
MX (1) MX2017008569A (enExample)
MY (1) MY185334A (enExample)
PE (2) PE20171154A1 (enExample)
PH (1) PH12017501222B1 (enExample)
SG (1) SG11201705376SA (enExample)
TN (1) TN2017000271A1 (enExample)
TW (1) TW201639878A (enExample)
UA (1) UA126960C2 (enExample)
WO (1) WO2016108586A1 (enExample)
ZA (1) ZA201705015B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188819A (ja) * 2014-12-30 2020-11-26 ハンミ ファーマシューティカル カンパニー リミテッド 安定性が増加されたグルカゴン誘導体
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
UA126662C2 (uk) 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
SG11202005510SA (en) * 2017-12-22 2020-07-29 Hanmi Pharmaceutical Co Ltd Therapeutic enzyme fusion protein having a novel structure and use thereof
EP3743097A1 (en) * 2018-01-23 2020-12-02 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
MX2021007124A (es) * 2018-12-21 2021-08-11 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que incluye insulina y glucagon.
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
US20230192800A1 (en) 2020-05-22 2023-06-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon derivative
EP4183407A4 (en) * 2020-07-15 2024-08-14 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A GLUCAGNONE DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASES
IL305549A (en) 2021-04-09 2023-10-01 Hanmi Pharm Ind Co Ltd Pharmaceutical composition for the prevention or treatment of chronic kidney disease including a glucagon derivative
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
PT1605897E (pt) 2003-03-19 2012-09-10 Lilly Co Eli Compostos de glp-1 ligado a polietilenoglicol
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
DK2172479T3 (en) 2007-06-19 2016-12-19 Glytech Inc GLP-1 peptide having the sugar chain attached thereto
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
RS53987B1 (sr) 2009-07-13 2015-10-30 Zealand Pharma A/S Analozi acilovanog glukagona
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
KR20120128129A (ko) 2010-01-20 2012-11-26 질랜드 파마 에이/에스 심장 병태의 치료
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012158965A2 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
DK2718318T3 (en) 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
AR086969A1 (es) * 2011-06-17 2014-02-05 Hanmi Science Co Ltd Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
HUE039267T2 (hu) 2012-06-21 2018-12-28 Univ Indiana Res & Tech Corp GIP-receptor aktivitást mutató glukagon-analógok
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PH12018501454A1 (en) 2012-11-06 2020-02-17 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment
WO2014081864A1 (en) 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
KR20160021758A (ko) * 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
AU2015372818A1 (en) 2014-12-30 2017-07-27 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20240215A1 (es) * 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
CN115920077B (zh) 2015-12-31 2025-07-04 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188819A (ja) * 2014-12-30 2020-11-26 ハンミ ファーマシューティカル カンパニー リミテッド 安定性が増加されたグルカゴン誘導体
JP7079301B2 (ja) 2014-12-30 2022-06-01 ハンミ ファーマシューティカル カンパニー リミテッド 安定性が増加されたグルカゴン誘導体
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11667688B2 (en) 2015-06-30 2023-06-06 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist

Also Published As

Publication number Publication date
MA40709A1 (fr) 2017-12-29
EA035527B1 (ru) 2020-06-30
PE20230304A1 (es) 2023-02-13
IL253206A0 (en) 2017-08-31
JP2020188819A (ja) 2020-11-26
UA126960C2 (uk) 2023-03-01
EP3241841A1 (en) 2017-11-08
NZ770767A (en) 2024-04-26
IL253206B (en) 2021-10-31
JP2018504901A (ja) 2018-02-22
AR103322A1 (es) 2017-05-03
CN107636009B (zh) 2021-04-16
MY185334A (en) 2021-05-06
CO2017006308A2 (es) 2017-09-29
KR20160082482A (ko) 2016-07-08
EA201791333A1 (ru) 2017-12-29
PH12017501222B1 (en) 2024-07-03
EP3575314A3 (en) 2020-01-22
KR102291020B1 (ko) 2021-08-20
CR20170293A (es) 2017-11-03
CA2972748A1 (en) 2016-07-07
WO2016108586A1 (ko) 2016-07-07
TN2017000271A1 (en) 2018-10-19
MA40709B1 (fr) 2019-07-31
PH12017501222A1 (en) 2018-01-15
US20170360892A1 (en) 2017-12-21
EP3575314C0 (en) 2024-02-14
AU2015372818A1 (en) 2017-07-27
IL281375B (en) 2021-10-31
ZA201705015B (en) 2018-04-25
GT201700150A (es) 2018-12-12
CL2017001718A1 (es) 2018-01-12
ECSP17040923A (es) 2017-12-01
SG11201705376SA (en) 2017-08-30
IL281375A (en) 2021-04-29
PE20171154A1 (es) 2017-08-16
EP3241841A4 (en) 2018-10-17
JP7079301B2 (ja) 2022-06-01
TW201639878A (zh) 2016-11-16
DOP2017000156A (es) 2017-10-15
NZ733464A (en) 2024-01-26
EP3575314A2 (en) 2019-12-04
CN107636009A (zh) 2018-01-26
BR112017014205A2 (pt) 2018-03-06
HK1248713A1 (en) 2018-10-19
US11135271B2 (en) 2021-10-05
EP3575314B1 (en) 2024-02-14
MX2017008569A (es) 2017-10-20
ES2976562T3 (es) 2024-08-05

Similar Documents

Publication Publication Date Title
JP7079301B2 (ja) 安定性が増加されたグルカゴン誘導体
CA3064214C (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US12018060B2 (en) Glucagon derivatives
CA2972748C (en) Glucagon derivatives with improved stability
HK40010066A (en) Glucagon derivative
HK40010066B (en) Glucagon derivative
BR112017014205B1 (pt) Derivados de glucagon e seu uso, e uso de uma composição farmacêutica
HK1246323B (en) Glucagon derivatives
NZ740049B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ734808B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ755534B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200828

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200904

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201117

R150 Certificate of patent or registration of utility model

Ref document number: 6797122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250